Literature DB >> 30094695

Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial.

Yuhui Zhu1, Elizabeth A Evans2, Larissa J Mooney1,3, Andrew J Saxon4, Annamarie Kelleghan5, Caroline Yoo1, Yih-Ing Hser6.   

Abstract

Opioid use disorder (OUD) is a chronic, relapsing condition with severe negative health consequences. Previous studies have reported that 5-year opioid abstinence is a good predictor of reduced likelihoods of relapse, but factors that shape long-term opioid abstinence are poorly understood. The present study is based on data from a prospective study of 699 adults with OUD who had been randomized to either methadone or buprenorphine/naloxone and who were followed for at least 5 years. During the 5 years prior to the participants' last follow-up interview, 232 (33.2%) had achieved 5-year abstinence from heroin. Of those 232, 145 (20.7% of the total) had remained abstinent from both heroin and other opioids (e.g., hydrocodone, oxycodone, other opioid analgesics, excluding methadone or buprenorphine). Compared to non-abstinent individuals, those in both categories of opioid abstinence had lower problem severity in health and social functioning at the final follow-up. Logistic regression results indicated that cocaine users and injection drug users were less likely to achieve 5-year heroin abstinence, whereas Hispanics (vs. whites) and those treated in clinics on the West Coast (vs. East) were less likely to achieve 5-year abstinence from heroin and other opioids. For both abstinence category groups, abstinence was positively associated with older age at first opioid use, lower impulsivity, longer duration of treatment for OUD, and greater social support. Reducing cocaine use and injection drug use and increasing social support and retention in treatment may help maintain long-term abstinence from opioids among individuals treated with agonist pharmacotherapy.

Entities:  

Keywords:  Buprenorphine; Methadone; Naloxone; Opioid use disorder; Pharmacotherapy

Mesh:

Substances:

Year:  2018        PMID: 30094695      PMCID: PMC6224303          DOI: 10.1007/s11481-018-9801-x

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  40 in total

1.  Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: a naturalistic study in 2694 patients.

Authors:  Hans-Ulrich Wittchen; Sabine M Apelt; Michael Soyka; Markus Gastpar; Markus Backmund; Jörg Gölz; Michael R Kraus; Felix Tretter; Martin Schäfer; Jens Siegert; Norbert Scherbaum; Jürgen Rehm; Gerhard Bühringer
Journal:  Drug Alcohol Depend       Date:  2008-03-11       Impact factor: 4.492

Review 2.  Quality of life as an outcome of opioid use disorder treatment: A systematic review.

Authors:  Jeremy W Bray; Brandon Aden; Ashley A Eggman; Leah Hellerstein; Eve Wittenberg; Bohdan Nosyk; Judy C Stribling; Bruce R Schackman
Journal:  J Subst Abuse Treat       Date:  2017-02-10

3.  Characterizing durations of heroin abstinence in the California Civil Addict Program: results from a 33-year observational cohort study.

Authors:  Bohdan Nosyk; M Douglas Anglin; Mary-Lynn Brecht; Viviane Dias Lima; Yih-Ing Hser
Journal:  Am J Epidemiol       Date:  2013-02-27       Impact factor: 4.897

4.  A 33-year follow-up of narcotics addicts.

Authors:  Y I Hser; V Hoffman; C E Grella; M D Anglin
Journal:  Arch Gen Psychiatry       Date:  2001-05

5.  Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study.

Authors:  Michael Soyka; Christina Zingg; Gabriele Koller; Heinrich Kuefner
Journal:  Int J Neuropsychopharmacol       Date:  2008-01-21       Impact factor: 5.176

6.  Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.

Authors:  Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss
Journal:  Drug Alcohol Depend       Date:  2013-01-18       Impact factor: 4.492

7.  Recovery from opioid addiction in DATOS.

Authors:  Patrick M Flynn; George W Joe; Kirk M Broome; D Dwayne Simpson; Barry S Brown
Journal:  J Subst Abuse Treat       Date:  2003-10

8.  The effect of baseline cocaine use on treatment outcomes for heroin dependence over 24 months: findings from the Australian Treatment Outcome Study.

Authors:  Anna Williamson; Shane Darke; Joanne Ross; Maree Teesson
Journal:  J Subst Abuse Treat       Date:  2007-02-22

9.  Predictors of heroin relapse: Personality traits, impulsivity, COMT gene Val158met polymorphism in a 5-year prospective study in Shanghai, China.

Authors:  Hang Su; Zhibin Li; Jiang Du; Haifeng Jiang; Zhikang Chen; Haiming Sun; Min Zhao
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2015-09-08       Impact factor: 3.568

10.  A Prospective Study to Investigate Predictors of Relapse among Patients with Opioid Use Disorder Treated with Methadone.

Authors:  Leen Naji; Brittany B Dennis; Monica Bawor; Carolyn Plater; Guillaume Pare; Andrew Worster; Michael Varenbut; Jeff Daiter; David C Marsh; Dipika Desai; Lehana Thabane; Zainab Samaan
Journal:  Subst Abuse       Date:  2016-04-10
View more
  13 in total

1.  Editors' Commentary for Special Issue: The 2017 CALDAR Summer Institute and International Conference Promoting Global Health-Precision Research in Substance Abuse, HIV, and Care.

Authors:  Linda Chang; Ming D Li; Yih-Ing Hser
Journal:  J Neuroimmune Pharmacol       Date:  2018-10-31       Impact factor: 4.147

2.  Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study.

Authors:  Andrea K Finlay; Erica Morse; Matthew Stimmel; Emmeline Taylor; Christine Timko; Alex H S Harris; David Smelson; Mengfei Yu; Jessica Blue-Howells; Ingrid A Binswanger
Journal:  J Gen Intern Med       Date:  2020-06-24       Impact factor: 5.128

3.  Trajectories of craving during medication-assisted treatment for opioid-use disorder: Subtyping for early identification of higher risk.

Authors:  Albert J Burgess-Hull; Leigh V Panlilio; Kenzie L Preston; David H Epstein
Journal:  Drug Alcohol Depend       Date:  2022-02-18       Impact factor: 4.492

4.  Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.

Authors:  Yuhui Zhu; Larissa J Mooney; Caroline Yoo; Elizabeth A Evans; Annemarie Kelleghan; Andrew J Saxon; Megan E Curtis; Yih-Ing Hser
Journal:  Drug Alcohol Depend       Date:  2021-08-28       Impact factor: 4.492

5.  I feel good? Anhedonia might not mean "without pleasure" for people treated for opioid use disorder.

Authors:  Samuel W Stull; Jeremiah W Bertz; Leigh V Panlilio; William J Kowalczyk; Karran A Phillips; Landhing M Moran; Jia-Ling Lin; Massoud Vahabzadeh; Patrick H Finan; Kenzie L Preston; David H Epstein
Journal:  J Abnorm Psychol       Date:  2021-07

Review 6.  Opioid agonist treatment for people who are dependent on pharmaceutical opioids.

Authors:  Suzanne Nielsen; Wai Chung Tse; Briony Larance
Journal:  Cochrane Database Syst Rev       Date:  2022-09-05

7.  Beyond abstinence and relapse: cluster analysis of drug-use patterns during treatment as an outcome measure for clinical trials.

Authors:  Leigh V Panlilio; Samuel W Stull; Jeremiah W Bertz; Albert J Burgess-Hull; William J Kowalczyk; Karran A Phillips; David H Epstein; Kenzie L Preston
Journal:  Psychopharmacology (Berl)       Date:  2020-09-29       Impact factor: 4.530

8.  Perceived social support in patients with chronic pain with and without opioid use disorder and role of medication for opioid use disorder.

Authors:  Julia R Benville; Peggy Compton; Nicholas A Giordano; Martin D Cheatle
Journal:  Drug Alcohol Depend       Date:  2021-02-15       Impact factor: 4.492

9.  Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada.

Authors:  Samantha Young; Kanna Hayashi; Cameron Grant; M J Milloy; Kora DeBeck; Evan Wood; Nadia Fairbairn
Journal:  Drug Alcohol Depend       Date:  2021-08-28       Impact factor: 4.492

10.  Opioid knowledge and perceptions among Hispanic/Latino residents in Los Angeles.

Authors:  Jennifer B Unger; Gregory B Molina; Melvin F Baron
Journal:  Subst Abus       Date:  2020-08-19       Impact factor: 3.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.